Drug Profile
rAAV2tYF-PR.1-hCNGA3 - Beacon Therapeutics
Alternative Names: ACHM A3; ACHM CNGA3; AGTC-402; recombinant Adeno-associated virus vector expressing CNGA3Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Applied Genetic Technologies Corporation
- Developer Beacon Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Colour vision defects
Most Recent Events
- 14 Feb 2022 Safety data from a phase I/II trial in Colour vision defects released by Applied Genetic Technologies Corporation
- 24 Jun 2021 Efficacy data from a phase I/II trial in Colour vision defects released by Applied Genetic Technologies Corporation
- 27 Jan 2021 Updated efficacy data from a phase I/II trial in Colour vision defects released by Applied Genetic Technologies Corporation